Pintos-Morell G - Search Results

1

Enzyme replacement therapy with agalsidase alfa in children with Fabry disease.

Ramaswami U, Wendt S, Pintos-Morell G, Parini R, Whybra C, Leon Leal JA, Santus F, Beck M. Ramaswami U, et al. Acta Paediatr. 2007 Jan;96(1):122-7. doi: 10.1111/j.1651-2227.2007.00029.x. Acta Paediatr. 2007. PMID: 17187618 Clinical Trial.

2

Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey.

Ramaswami U, Parini R, Pintos-Morell G, Kalkum G, Kampmann C, Beck M; FOS Investigators. Ramaswami U, et al. Clin Genet. 2012 May;81(5):485-90. doi: 10.1111/j.1399-0004.2011.01671.x. Epub 2011 Apr 25. Clin Genet. 2012. PMID: 21457233

3

Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey.

Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G, Widmer U, Beck M; FOS European Investigators. Ramaswami U, et al. Acta Paediatr. 2006 Jan;95(1):86-92. doi: 10.1080/08035250500275022. Acta Paediatr. 2006. PMID: 16498740

4

Fabry disease and the skin: data from FOS, the Fabry outcome survey.

Orteu CH, Jansen T, Lidove O, Jaussaud R, Hughes DA, Pintos-Morell G, Ramaswami U, Parini R, Sunder-Plassman G, Beck M, Mehta AB; FOS Investigators. Orteu CH, et al. Br J Dermatol. 2007 Aug;157(2):331-7. doi: 10.1111/j.1365-2133.2007.08002.x. Epub 2007 Jun 15. Br J Dermatol. 2007. PMID: 17573884

5

Fabry disease in children and the effects of enzyme replacement treatment.

Pintos-Morell G, Beck M. Pintos-Morell G, et al. Eur J Pediatr. 2009 Nov;168(11):1355-63. doi: 10.1007/s00431-009-0937-9. Epub 2009 Feb 26. Eur J Pediatr. 2009. PMID: 19242721 Free PMC article.

6

Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ).

Ramaswami U, Stull DE, Parini R, Pintos-Morell G, Whybra C, Kalkum G, Rohrbach M, Raluy-Callado M, Beck M, Chen WH, Wiklund I; FOS Investigators. Ramaswami U, et al. Health Qual Life Outcomes. 2012 Sep 20;10:116. doi: 10.1186/1477-7525-10-116. Health Qual Life Outcomes. 2012. PMID: 22992222 Free PMC article.

7

Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis.

Ramaswami U, Beck M, Hughes D, Kampmann C, Botha J, Pintos-Morell G, West ML, Niu DM, Nicholls K, Giugliani R; FOS Study Group. Ramaswami U, et al. Drug Des Devel Ther. 2019 Oct 25;13:3705-3715. doi: 10.2147/DDDT.S207856. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31749608 Free PMC article.

8

Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age.

Parini R, Pintos-Morell G, Hennermann JB, Hsu TR, Karabul N, Kalampoki V, Gurevich A, Ramaswami U; FOS Study Group. Parini R, et al. Drug Des Devel Ther. 2020 Jun 3;14:2149-2158. doi: 10.2147/DDDT.S249433. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 32581513 Free PMC article.

9

Paediatric Fabry disease: prognostic significance of ocular changes for disease severity.

Kalkum G, Pitz S, Karabul N, Beck M, Pintos-Morell G, Parini R, Rohrbach M, Bizjajeva S, Ramaswami U. Kalkum G, et al. BMC Ophthalmol. 2016 Nov 16;16(1):202. doi: 10.1186/s12886-016-0374-2. BMC Ophthalmol. 2016. PMID: 27852300 Free PMC article.

10

Long-term outcomes with agalsidase alfa enzyme replacement therapy: Analysis using deconstructed composite events.

Beck M, Hughes D, Kampmann C, Pintos-Morell G, Ramaswami U, West ML, Giugliani R. Beck M, et al. Mol Genet Metab Rep. 2017 Nov 9;14:31-35. doi: 10.1016/j.ymgmr.2017.10.008. eCollection 2018 Mar. Mol Genet Metab Rep. 2017. PMID: 29159077 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

77 results

Search Page